Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Payables (2016 - 2025)

Historic Payables for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $22.3 million.

  • Regenxbio's Payables rose 1405.59% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.3 million, marking a year-over-year increase of 1405.59%. This contributed to the annual value of $22.8 million for FY2024, which is 5.27% up from last year.
  • Latest data reveals that Regenxbio reported Payables of $22.3 million as of Q3 2025, which was up 1405.59% from $21.7 million recorded in Q2 2025.
  • Regenxbio's 5-year Payables high stood at $31.4 million for Q1 2024, and its period low was $9.4 million during Q2 2021.
  • For the 5-year period, Regenxbio's Payables averaged around $19.9 million, with its median value being $21.7 million (2025).
  • As far as peak fluctuations go, Regenxbio's Payables surged by 13898.31% in 2022, and later tumbled by 3926.52% in 2025.
  • Quarter analysis of 5 years shows Regenxbio's Payables stood at $11.4 million in 2021, then soared by 138.98% to $27.2 million in 2022, then fell by 16.27% to $22.8 million in 2023, then increased by 0.05% to $22.8 million in 2024, then fell by 2.33% to $22.3 million in 2025.
  • Its last three reported values are $22.3 million in Q3 2025, $21.7 million for Q2 2025, and $19.0 million during Q1 2025.